Bruker Co. (NASDAQ:BRKR) Stock Position Lessened by Kennedy Capital Management Inc.

Kennedy Capital Management Inc. lessened its stake in shares of Bruker Co. (NASDAQ:BRKR) by 24.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 395,316 shares of the medical research company’s stock after selling 126,449 shares during the quarter. Kennedy Capital Management Inc. owned approximately 0.25% of Bruker worth $15,196,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of BRKR. Citigroup Inc. grew its holdings in Bruker by 32.3% in the 1st quarter. Citigroup Inc. now owns 44,764 shares of the medical research company’s stock valued at $1,720,000 after buying an additional 10,935 shares during the period. WCM Investment Management LLC purchased a new stake in Bruker in the 1st quarter valued at about $1,624,000. Dynamic Technology Lab Private Ltd purchased a new stake in Bruker in the 1st quarter valued at about $1,364,000. Jennison Associates LLC purchased a new stake in Bruker in the 1st quarter valued at about $593,000. Finally, AlphaCrest Capital Management LLC purchased a new stake in Bruker in the 1st quarter valued at about $1,772,000. Hedge funds and other institutional investors own 66.73% of the company’s stock.

In other Bruker news, CEO Frank H. Laukien sold 400,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $41.48, for a total value of $16,592,000.00. Following the transaction, the chief executive officer now directly owns 37,991,030 shares of the company’s stock, valued at approximately $1,575,867,924.40. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Marc A. Kastner sold 1,374 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $41.79, for a total value of $57,419.46. Following the completion of the transaction, the director now directly owns 10,811 shares in the company, valued at $451,791.69. The disclosure for this sale can be found here. Insiders have sold a total of 801,374 shares of company stock worth $33,241,419 over the last three months. 26.50% of the stock is currently owned by corporate insiders.

Several analysts have commented on BRKR shares. Jefferies Financial Group lifted their price target on Bruker from $45.00 to $56.00 and gave the company a “buy” rating in a report on Friday, June 21st. BidaskClub upgraded Bruker from a “buy” rating to a “strong-buy” rating in a report on Friday, March 22nd. Svb Leerink upgraded Bruker from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $40.00 to $53.00 in a report on Friday, May 3rd. Leerink Swann upgraded Bruker from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. Finally, Needham & Company LLC reiterated a “strong-buy” rating and set a $46.00 target price (up previously from $39.00) on shares of Bruker in a report on Monday, May 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Bruker presently has an average rating of “Buy” and a consensus target price of $48.20.

Bruker stock traded up $1.00 during midday trading on Friday, hitting $49.95. 629,437 shares of the company were exchanged, compared to its average volume of 755,864. The stock has a fifty day simple moving average of $44.19. The company has a market cap of $7.57 billion, a P/E ratio of 35.68, a PEG ratio of 2.37 and a beta of 1.26. The company has a current ratio of 2.12, a quick ratio of 1.27 and a debt-to-equity ratio of 0.42. Bruker Co. has a fifty-two week low of $26.10 and a fifty-two week high of $51.13.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.24 by $0.04. The firm had revenue of $461.40 million for the quarter, compared to analyst estimates of $450.46 million. Bruker had a return on equity of 26.28% and a net margin of 9.53%. Bruker’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.24 EPS. On average, sell-side analysts predict that Bruker Co. will post 1.62 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, June 21st. Investors of record on Monday, June 3rd were given a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a yield of 0.32%. The ex-dividend date was Friday, May 31st. Bruker’s dividend payout ratio (DPR) is presently 11.43%.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Further Reading: Diversification

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.